Impact on patients

AI is helping to improve the experience for patients at every stage of their journey. It can quickly match individuals to clinical trials that fit their needs, making it easier to find appropriate opportunities. With automated systems guiding patients through the consent process, enrollment becomes simpler and easier. Patients are no longer faced with long and complex forms. By making these documents easier to understand and providing interactive support, AI improves clarity and engagement, reduces patient confusion, and eliminates administrative delays.

Once patients are enrolled, AI enables better trial designs that select the right patients, ensuring the optimal benefit-risk balance. Early protocol assessments driven by AI can minimize patient burden (i.e., eliminating unnecessary site visits or biopsies). During clinical trials, AI-driven digital tools provide timely information, reminders and support, helping inform and retain patients. These improvements reduce administrative burdens, speed up access to new therapies, and ultimately create a smoother, more supportive experience for both patients and their caregivers.

Following successful trials, AI shortens the path to market for effective therapies. Commercialization in life sciences is all about timing, creation and impact. Current AI capabilities make the final data analysis, reporting and submission process easier, more efficient, and higher quality. Al supports launching a drug at the right time, creating positive patient impacts and bringing precision to brand messaging. These factors help transform go-to-market strategies. AI ensures that every launch, every campaign, and every engagement across life sciences stakeholders are timely and impactful.

Successful AI: The power of connected, high-quality inputs

Strategic initiatives, such as our work with NVIDIA, benefit our customers by bringing advanced infrastructure and additional technical expertise to IQVIA’s agentic AI solutions.

At IQVIA, we deliver this level of connectivity through our proprietary data assets, advanced technologies, and deep domain expertise. IQVIA Connected Intelligence^™ brings together information from multiple sources, empowering our AI to generate informed, actionable insights and accelerate the journey from molecule to market. This foundation supports our Healthcare-grade AI^®, which is designed to be transparent, explainable and governed by rigorous standards, ensuring trust and reliability for our clients.

Strategic partnerships, such as our collaboration with NVIDIA, benefit our customers by bringing advanced infrastructure and additional technical expertise to IQVIA’s agentic AI solutions. For organizations, this means expedited processes, improved quality, and faster access to powerful, scalable AI tools that are continually refined to meet evolving industry needs. By leveraging these partnerships, our customers can accelerate innovation, improve decision-making and achieve better outcomes for patients and stakeholders.

AI’s end-to-end impact

By improving success rates, reducing timelines, enhancing quality, and delivering better stakeholder experiences, AI is transforming how therapies are developed and delivered from start to finish. At IQVIA, we are working at the cutting edge of these advanced technologies. Together with our clients, we are fundamentally reimagining paths to innovation, ensuring treatments reach the right patients faster, with greater confidence and lasting impact.

To explore how AI solutions can benefit your organization, visit iqvia.com/AI.

References:

IDC, Worldwide GenAI Industry Use Case Early Adoption Trends, 2025: Life Sciences, doc # US53317424, April 2025